USPTO Examiner YOO SUN JAE - Art Unit 1621

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18938926CABOZANTINIB COMPOSITIONS AND METHODS OF USENovember 2024May 2025Allow611NoNo
18618379SALT OF AN AMINOPYRIDINE DERIVATIVE COMPOUND, A CRYSTALLINE FORM THEREOF, AND A PROCESS FOR PREPARING THE SAMEMarch 2024July 2025Allow1521YesNo
18617723NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERSMarch 2024April 2025Allow1301NoNo
18612849COMPOUNDS AND THEIR USEMarch 2024April 2025Allow1301NoNo
18421849SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALTJanuary 2024June 2025Allow1701NoNo
18545932COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERSDecember 2023July 2024Allow700YesNo
18520156SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALTNovember 2023December 2024Allow1312YesNo
18385025NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORSOctober 2023November 2024Allow1201NoNo
18476050SOLID FORMS AND COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOFSeptember 2023August 2024Allow1110NoNo
18465768COMPOSITIONS, KITS, AND METHODS TO INDUCE ACQUIRED CYTORESISTANCE USING STRESS PROTEIN INDUCERSSeptember 2023April 2024Allow711NoNo
18234608PLASMA KALLIKREIN INHIBITORS AND USES THEREOFAugust 2023August 2024Allow1201NoNo
18365392BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USEAugust 2023November 2024Abandon1601NoNo
18365044MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USEAugust 2023January 2025Abandon1701NoNo
18351283TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORSJuly 2023April 2025Allow2111NoNo
18213082ANTITUMORAL COMPOUNDSJune 2023March 2025Allow2111NoNo
18332566TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USEJune 2023May 2024Allow1101NoNo
18136661PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOFApril 2023August 2024Allow1601NoNo
18136734THERAPEUTIC COMPOUNDS AND COMPOSITIONSApril 2023May 2025Abandon2501NoNo
18133060FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIAApril 2023December 2024Allow2011NoNo
18124427ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERSMarch 2023April 2024Allow1311NoNo
18181099ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOFMarch 2023July 2024Allow1621NoNo
18172742BICYCLIC ENONE CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOFFebruary 2023September 2024Abandon1801NoNo
18112402CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAMEFebruary 2023January 2025Allow2311NoNo
18166178CDK2 INHIBITORSFebruary 2023February 2024Allow1221NoNo
18099875CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAMEJanuary 2023July 2024Allow1801NoNo
17928519Nitrosation Reagents and MethodsNovember 2022June 2025Allow3000NoNo
18049652PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORSOctober 2022May 2024Allow1811NoNo
18046011MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USEOctober 2022May 2024Abandon1901NoNo
17959920ENANTIOMERS OF A2-73, ANALOGUES, AND SIGMA AGONIST ACTIVITYOctober 2022September 2024Allow2311YesNo
17953935CRYSTALLINE SALTS OF PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITORSeptember 2022September 2023Allow1201NoNo
17930695SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALTSeptember 2022January 2025Abandon2821YesNo
17929656METHODS OF TREATING GLIOBLASTOMASeptember 2022January 2024Abandon1701NoNo
17896767EBNA1 Inhibitor Crystalline Forms, and Methods of Preparing and Using SameAugust 2022June 2024Allow2111NoNo
17894700ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAMEAugust 2022November 2023Allow1501NoNo
17816855OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORSAugust 2022August 2024Allow2411NoNo
17816281CXCR7 INHIBITORS FOR THE TREATMENT OF CANCERJuly 2022March 2025Abandon3121NoNo
17870573COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERSJuly 2022October 2023Allow1501NoNo
17858233PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AGING-RELATED DISEASESJuly 2022November 2024Abandon2911NoNo
17810367COMPOUNDS AND THEIR USEJuly 2022March 2024Allow2011NoNo
17855414METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONESJune 2022January 2024Allow1811NoNo
17850453CDK2 INHIBITORSJune 2022January 2024Allow1811NoNo
17844921DIACYLGLYCEROL KINASE MODULATING COMPOUNDSJune 2022February 2024Allow2011NoNo
17845534DIACYLGLYCEROL KINASE MODULATING COMPOUNDSJune 2022January 2024Allow1911NoNo
17845142BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORSJune 2022February 2024Allow2001NoNo
17845499Method of Manufacture for Liquid Cannabinoids, and Modified CBD Oil CompositionJune 2022January 2024Abandon1901NoNo
17843197COMPOSITIONS PROVIDING SLOW RELEASE OF CAFFEINEJune 2022April 2025Allow3412NoNo
17842158Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives ThereofJune 2022November 2024Abandon2921NoNo
17840957BCL-2 INHIBITORSJune 2022January 2024Allow1911NoNo
17828643BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITYMay 2022September 2024Abandon2712YesNo
17826289ORAL AQUEOUS SUSPENSION FORMULATION COMPRISING CARBAMATE COMPOUNDMay 2022October 2024Allow2921NoNo
17776952COMPOUNDS AND USES THEREOFMay 2022November 2024Allow3011NoNo
177444325,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASESMay 2022July 2024Abandon2621NoNo
17738872HETEROCYCLIC PROLINAMIDE DERIVATIVESMay 2022May 2024Abandon2512NoNo
17736057TIMOSAPONIN COMPOUNDSMay 2022October 2024Allow3012NoNo
17661274USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATION AND AGING IN THE SKINApril 2022November 2023Abandon1801NoNo
17755100Process for preparing glycerol carbonate (meth)acrylateApril 2022June 2025Allow3800NoNo
17726120METHODS, COMPOSITIONS, KITS AND USES THEREOF TARGETING AND/OR TREATING VRK2 TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR(S)April 2022April 2025Allow3521NoNo
17754703QUINOLONE CARBOXYLIC DERIVATIVESApril 2022February 2025Allow3500NoNo
17716645P53-DESTABILIZING PROTEIN ASSOCIATED WITH PROTO-ONCOGENE STEMNESS AS A THERAPEUTIC TARGET AND INHIBITORS THEREOF FOR USE IN TREATMENT OF CANCERApril 2022March 2024Allow2411NoNo
17714114Antitumoral CompoundsApril 2022January 2023Allow911NoNo
17761868AN IMPROVED PROCESS FOR 4-(HYDROXYMETHYL)-5-METHYL-1,3-DIOXOL-2-ONEMarch 2022April 2025Allow3710NoNo
17655262FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOFMarch 2022September 2024Abandon3021YesNo
17697655SALT OF AN AMINOPYRIDINE DERIVATIVE COMPOUND, A CRYSTALLINE FORM THEREOF, AND A PROCESS FOR PREPARING THE SAMEMarch 2022September 2023Allow1801YesNo
17760878SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERSMarch 2022January 2025Abandon3401NoNo
17642629THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDSMarch 2022April 2025Allow3701NoNo
176403871,3-BUTYLENE GLYCOL PRODUCTMarch 2022March 2025Allow3600NoNo
176405141,3-BUTYLENE GLYCOL PRODUCTMarch 2022February 2025Allow3600NoNo
17753270ACRYLATE AND SILICONE-FREE COSMETIC O/W EMULSIONFebruary 2022February 2025Allow3600NoNo
17670423TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORSFebruary 2022April 2023Allow1401NoNo
17577456PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USESJanuary 2022August 2024Allow3121YesNo
17571838EXTERNAL DERMAL COMPOSITION AND METHOD FOR BEAUTIFYING SKINJanuary 2022September 2023Allow2001NoNo
17623129ACRYLATE DERIVATIVE, USE AND PRODUCTION INTERMEDIATE COMPOUND OF THE SAMEDecember 2021May 2024Allow2812YesNo
17618428NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERSDecember 2021January 2025Abandon3701NoNo
17457269MPO INHIBITORS FOR USE IN MEDICINEDecember 2021April 2023Allow1601NoNo
17534679PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVESNovember 2021August 2023Abandon2101NoNo
17528532PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORSNovember 2021September 2024Allow3432NoNo
17527475PEPTOID-BASED INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE (PRMT) FAMILYNovember 2021February 2024Allow2711NoNo
17514356Fluorogenic Probe Using a Mislow-Evans Rearrangement for Real-Time Imaging of Hydrogen PeroxideOctober 2021January 2024Allow2611YesNo
17506324COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USEOctober 2021January 2024Abandon2711YesNo
17500140FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORSOctober 2021December 2023Allow2611NoNo
17599868PROCESS FOR MAKING SIPONIMOD AND INTERMEDIATE THEREOFSeptember 2021May 2025Allow4401NoNo
17599823METHOD FOR EXTRACTING AND SEPARATING DIHYDROMYRICETIN FROM RATTAN TEASeptember 2021March 2024Allow3011YesNo
17449398THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOFSeptember 2021March 2024Abandon2911NoNo
17598342INHIBITORS OF HISTONE DEACETYLASE-3 USEFUL FOR THE TREATMENT OF CANCER, INFLAMMATION, NEURODEGENERATION DISEASES AND DIABETESSeptember 2021December 2024Allow3801NoNo
17448833SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALTSeptember 2021October 2023Allow2501YesNo
17442246Complement Modulators and Related MethodsSeptember 2021January 2025Abandon4001NoNo
17440780COMBINATION OF MINOCYCLINE AND BENZOYL PEROXIDE AND METHOD OF USE THEREOFSeptember 2021June 2025Abandon4501NoNo
17440468QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCERSeptember 2021December 2024Allow3911NoNo
17440362PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFORSeptember 2021March 2025Abandon4201NoNo
17439903COMPOSITIONS AND METHODS FOR ENHANCING CANCER IMMUNE CHECKPOINT THERAPYSeptember 2021June 2025Allow4501NoNo
17440147NOVEL INHIBITORS OF HISTONE DEACETYLASE 10September 2021January 2025Abandon4001NoNo
17439995ROSCOVITINE ANALOGUES AND USE THEREOF FOR TREATING RARE BILIARY DISEASESSeptember 2021January 2025Abandon4001NoNo
17439735NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORSSeptember 2021August 2024Allow3521YesNo
17439578COMPOSITION COMPRISING BORNYL ACETATE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF STRESS-RELATED DISORDERSeptember 2021February 2025Allow4112NoNo
17469983STING AGONIST COMPOUNDS AND METHODS OF USESeptember 2021November 2023Allow2611NoNo
17437144ABIRATERONE-CYCLIC OLIGOMER PHARMACEUTICAL FORMULATIONS AND METHODS OF FORMATION AND ADMINISTRATION THEREOFSeptember 2021May 2025Abandon4401NoNo
17436500PYRROLOPYRAZOLE DERIVATIVESeptember 2021September 2024Allow3701NoNo
17435855SUMO INHIBITOR COMPOUNDS AND USES THEREOFSeptember 2021April 2025Allow4301NoNo
17435678COMPOUNDS FOR PREVENTION AND TREATMENT OF OBESITY AND RELATED DISORDERSSeptember 2021April 2025Allow4411NoNo
17435095OPHTHALMIC COMPOSITION OF BIMATOPROSTAugust 2021August 2024Abandon3501NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner YOO, SUN JAE.

Strategic Value of Filing an Appeal

Total Appeal Filings
12
Allowed After Appeal Filing
6
(50.0%)
Not Allowed After Appeal Filing
6
(50.0%)
Filing Benefit Percentile
75.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner YOO, SUN JAE - Prosecution Strategy Guide

Executive Summary

Examiner YOO, SUN JAE works in Art Unit 1621 and has examined 339 patent applications in our dataset. With an allowance rate of 82.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner YOO, SUN JAE's allowance rate of 82.6% places them in the 49% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by YOO, SUN JAE receive 1.48 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by YOO, SUN JAE is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +17.5% benefit to allowance rate for applications examined by YOO, SUN JAE. This interview benefit is in the 63% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.0% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 44.8% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 86.7% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 23.6% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 11.4% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.